% | $
Quotes you view appear here for quick access.

Regulus Therapeutics Inc. Message Board

  • gladysz gladysz Nov 20, 2013 1:32 PM Flag

    Press release on milestone payments

    Not a bad sign, this must be the catalyst for the 8% pop today:

    "We are very excited about our early success in this collaboration and are hopeful that our efforts advance Biogen Idec's work in treating MS," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "Further, we believe that achievement of this milestone assigns significant value to our proprietary technology and demonstrates the potential of our emerging biomarkers platform to support our microRNA therapeutic pipeline." Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.

8.45-0.79(-8.55%)Sep 3 4:00 PMEDT